ETH spin-off Scailyte, offering an artificial intelligence platform for the discovery of complex disease patterns from single-cell data, has closed the first round of the Series a round with new and existing investors. New biotech experts have also joined the startup.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
The startup has set the focus on expanding the capabilities of its single-cell analytics platform, ScaiVision™. The company is planning to establish further partnerships in immuno-oncology, and it is working on a custom solution to enable faster development of more robust cell therapies to enhance quality assessment of the manufacturing product, among other applications in this field. In order to broaden its service offering, Scailyte is also seeking strategic partnerships among complementary AI-driven companies.
In 2021 Scailyte implemented an ISO:9001-compliant Quality Management System (QMS). The new QMS will be instrumental in the scale-up phase of the company and will help ensure the high quality of Scailyte’s discovery activities.
The company has now obtained fresh capital as part of its first round of the series A round. Two investors and existing shareholders engaged with follow-on investments participated in the round. The capital will flow into developments and achieving its plans. The second closing is planned for the first half of 2022 and Scailyte is currently in discussions with a number of additional investors.
Biotech leaders join Scailyte
In line with the round, the startup has added executive talent to its core team, the Board of Directors (BoD) and the Scientific Advisory Board (SAB).
Marco Ruella, MD joined the SAB in December 2021. He is an Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania.
Corinne Solier assumed the role of COO position in November 2021. Formerly at Roche and a leader in the field of translational sciences, biomarkers and omics technologies, she is spearheading Scailyte’s discovery arm, the ScaiVision business unit. The new unit’s mission is to become Scailyte’s core discovery platform, leveraging clinical and molecular data integration, artificial intelligence and a network of clinical and industry partners. ScaiVision provides biomarker discovery and single-cell analytics services to precision medicine and immuno-oncology companies.
Anna Sumeray joined Scailyte’s BoD in November 2021. Anna is the CEO of Virometix, a University of Zurich spin-out company developing novel vaccines for the treatment and prevention of cancer and infectious diseases. She has over 20 years of experience in both large Pharma and start-up Biotechs and has held leadership roles in Business Development and General Management.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines